Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00352534 · ClinicalTrials.gov registry record · Phase 3

Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

A Phase 3 study of Stage III Kidney Wilms Tumor and Stage II Kidney Wilms Tumor, sponsored by Children's Oncology Group.

Active
Registry status
Phase 3
Development phase
808
Enrollment target
20
Study locations

NCT00352534: Active Phase 3 study of Stage III Kidney Wilms Tumor and Stage II Kidney Wilms Tumor, sponsored by Children's Oncology Group.

NCT00352534 is a Phase 3 study of Stage III Kidney Wilms Tumor and Stage II Kidney Wilms Tumor that is active but no longer recruiting, run by Children's Oncology Group. The registered enrollment target is 808 participants, above the 300-participant average among 3 other Stage III Kidney Wilms Tumor trials with a reported enrollment target (169% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00352534, a Phase 3 study of Stage III Kidney Wilms Tumor and Stage II Kidney Wilms Tumor, is active but no longer recruiting, sponsored by Children's Oncology Group.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
808 participants
Enrollment target
20
Study locations

Study Summary

This phase III trial is studying vincristine, dactinomycin, and doxorubicin with or without radiation therapy or observation only to see how well they work in treating patients undergoing surgery for newly diagnosed stage I, stage II, or stage III Wilms' tumor. Drugs used in chemotherapy, such as vincristine, dactinomycin, and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors.Giving these treatments after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient.

Primary Outcome

Probability of no relapse, secondary malignancy, or death after 4 year in the study.

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Chest Radiography
  • BIOLOGICAL Dactinomycin
  • RADIATION 3-Dimensional Conformal Radiation Therapy

Study Locations (20)

California

  • Kaiser Permanente Downey Medical Center - Downey
  • City of Hope Comprehensive Cancer Center - Duarte
  • Loma Linda University Medical Center - Loma Linda
  • Miller Children's and Women's Hospital Long Beach - Long Beach
  • Children's Hospital Los Angeles - Los Angeles
  • Cedars Sinai Medical Center - Los Angeles
  • Valley Children's Hospital - Madera
  • UCSF Benioff Children's Hospital Oakland - Oakland
  • Kaiser Permanente-Oakland - Oakland
  • Children's Hospital of Orange County - Orange
  • Lucile Packard Children's Hospital Stanford University - Palo Alto
  • Sutter Medical Center Sacramento - Sacramento
  • University of California Davis Comprehensive Cancer Center - Sacramento

Alabama

  • Children's Hospital of Alabama - Birmingham
  • University of Alabama at Birmingham Cancer Center - Birmingham
  • USA Health Strada Patient Care Center - Mobile

Arizona

  • Phoenix Childrens Hospital - Phoenix
  • Banner University Medical Center - Tucson - Tucson

Arkansas

  • Arkansas Children's Hospital - Little Rock
  • University of Arkansas for Medical Sciences - Little Rock

Trial Details

FieldValue
Enrollment Target 808 participants
Start Date 2006-11-06
Est. Completion 2026-03-31
Phase Phase 3
Children's Oncology Group

342 total trials

What the registry record for NCT00352534 still lists

NCT00352534 is an interventional study that assigns participants to a tested intervention. The registered 808 participants enrollment target is mid-sized for trials with a published cap, above the 300-participant average among 3 other Stage III Kidney Wilms Tumor trials with a reported enrollment target (169% higher).

The record links to 3 conditions, with Stage III Kidney Wilms Tumor appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT00352534 names 20 study sites across 4 states, led by California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT00352534 about?

NCT00352534 is a clinical study titled "Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor". This phase III trial is studying vincristine, dactinomycin, and doxorubicin with or without radiation therapy or observation only to see how well they work in treating patients undergoing surgery for newly diagnosed stage I, stage II, or stage III Wilms' tumor. Drugs used in chemotherapy, such as vi...

What is the current status of trial NCT00352534?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 808 participants. The study started on 2006-11-06. Estimated completion is 2026-03-31.

What conditions does trial NCT00352534 study?

This clinical trial studies the following conditions: Stage III Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage I Kidney Wilms Tumor.

What interventions are being tested in trial NCT00352534?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Chest Radiography (PROCEDURE), Dactinomycin (BIOLOGICAL), 3-Dimensional Conformal Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT00352534?

This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00352534 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stage III Kidney Wilms Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06529094 · 808 participants · NA

    Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic

  • NCT05519085 · 810 participants · Phase 3

    A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

  • NCT04613596 · 806 participants · Phase 2

    Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • NCT06065098 · 806 participants · NA

    Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00352534, the US trial registry maintained by the National Library of Medicine. NCT00352534 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.